Table 1. Demographics and Clinical Features of Study Population.

	No Neoadjuvant (N = 87)	FOLFIRINOX (N = 40)	P
Male	45 (51.7%)	21 (52.5%)	0.999
Age, median (range), yr	70 (44–88)	62 (38–77)	<0.001
Median Ca19-9	140 (0–20,000)	169 (1–4754)
Charlson comorbidity score, median (range)	3 (1–11)	2 (0–5)	<0.001
ECOG performance status	0 = 44 (50.6%)	0 = 30 (75%)	0.013
	1 = 34 (39.1%)	1 = 10 (25%)
	2 = 9 (10.3%)	2 = 0
BMI, kg/m2	27.3 (18.5–50.1)	24.5 (19.1–43.2)	0.038
Weight loss > 5 kg	32 (36.8%)	19 (47.5%)	0.330
Complete cycles FOLFIRINOX, median (range)	0	8 (1–24)